China Pharma Holdings (CPHI) Total Current Liabilities (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Total Current Liabilities came in at $7.3 million in Q1 2026, up 41.89% YoY from $5.1 million in Q1 2025, and down 1.79% on a QoQ basis from $7.4 million in Q4 2025.
China Pharma Holdings (CPHI) Total Current Liabilities (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Total Current Liabilities data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 41.89% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 41.89% YoY) and the FY2025 annual result came in at $7.4 million, up 47.5% from the prior year.
- Total Current Liabilities retreated to $7.3 million in Q1 2026, from $7.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $12.7 million in Q4 2022 to a low of $4.7 million in Q2 2024.
- A 5-year average of $7.8 million and a median of $7.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 55.32% — and 2025, when it jumped 47.5%.
- Tracing CPHI's Total Current Liabilities over 5 years: stood at $12.7 million in 2022, then slumped by 46.46% to $6.8 million in 2023, then retreated by 26.44% to $5.0 million in 2024, then soared by 47.5% to $7.4 million in 2025, then slipped by 1.79% to $7.3 million in 2026.
- The last three Total Current Liabilities figures came in at $7.3 million (Q1 2026), $7.4 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.79 Bn |
| 10 | China Pharma Holdings | 42.70 Mn | 42.39 Mn | 83,566.00 | 7.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.27 Mn |
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 6.62 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Mar 31, 2025 | 5.12 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 4.76 Mn |
| Jun 30, 2024 | 4.71 Mn |
| Mar 31, 2024 | 5.73 Mn |
| Dec 31, 2023 | 6.82 Mn |
| Sep 30, 2023 | 7.06 Mn |
| Jun 30, 2023 | 10.55 Mn |
| Mar 31, 2023 | 11.92 Mn |
| Dec 31, 2022 | 12.74 Mn |
| Sep 30, 2022 | 12.63 Mn |
| Jun 30, 2022 | 8.36 Mn |
| Mar 31, 2022 | 9.90 Mn |
| Dec 31, 2021 | 10.51 Mn |
| Sep 30, 2021 | 10.45 Mn |
| Jun 30, 2021 | 12.19 Mn |